CoChat
Sign Up
Cited by 273Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record.

Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

Porsteinsson, Anton, Grossberg, George, Mintzer, Jacobo, Olin, Jason·2008·Current Alzheimer Research
DOI 10.2174/156720508783884576
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. METHODS: Participants (N= 433) with probable AD, Mini-Mental State Exam (MMSE) scores between 10-22 (inclusive), and concurrent stable use of ChEIs (donepezil, rivastigmine, galantamine) were randomized to placebo or memantine (20 mg once daily) for 24 weeks. Primary outcomes were changes from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and on Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) score. Secondary measures comprised the 23-item Alzheimer Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL(23)), Neuropsychiatric Inventory (NPI), and MMSE. RESULTS: At the end of the trial, there were no statistically significant differences between the memantine- and placebo group on primary and secondary outcome measures. The incidence of adverse events (AEs) was similar between the two groups, with no AE occurring in more than 5% of memantine-treated patients and at a rate twice that of the placebo group. CONCLUSIONS: In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens. There were no significant differences in tolerability and safety between the memantine- and placebo groups.

Overview

Integrity signals

Registry

Crossref · 10.2174/156720508783884576

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 201–273 of 273

Related

See all

Metadata

Authors
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J.
Affiliations
University of Rochester Medicine (US)
ORCID
Venue
Current Alzheimer Research
Publisher
Bentham Science Publishers Ltd.
Published
2008-02-01
Volume
5
Issue
1
Pages
83-89
ISSN
1567-2050 (ISSN-L)
DOI
10.2174/156720508783884576
OpenAlex
W2149626554
Cited by
272
References
0
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 7 · 2022: 13 · 2021: 9 · 2020: 8 · 2019: 17 · 2018: 9 · 2017: 12 · 2016: 16 · 2015: 21 · 2014: 17 · 2013: 22 · 2012: 28
FWCI
17.52
Type
journal article
Language
en
Open access
closed
Locations
  • Current Alzheimer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
memantine, Alzheimer's disease, cholinesterase inhibitors, donepezil, rivastigmine, galantamine, combination therapy, cognitive function, activities of daily living, neuropsychiatric symptoms, drug safety, tolerability
MeSH terms
Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Therapy, Combination, Humans, Memantine, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Prospective Studies, Severity of Illness Index, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review